VITALS Podcast Por Cloudcast arte de portada

VITALS

VITALS

De: Cloudcast
Escúchala gratis

OFERTA POR TIEMPO LIMITADO. Obtén 3 meses por US$0.99 al mes. Obtén esta oferta.
VITALS, the pulse of Georgia life sciences, brings together the leaders, the thinkers, the movers, and shakers who are putting Georgia firmly in a leadership position for what is widely known as "the biology century."

These closely curated conversations are led by the President & CEO of Georgia Life Sciences, Maria Thacker Goethe. Whether it is exploring topics from policy matters and venture funding to legislative matters and artificial intelligence, Maria expertly navigates and explores to flesh out actionable information from world class guests.

VITALS is brought to the community by Georgia Life Sciences in conjunction with Cloudcast Atlanta, a division of Cloudcast Media.

About Georgia Life Sciences


About Cloudcast Atlanta and Cloudcast Media2025 Ciencia Política Economía Gestión y Liderazgo Liderazgo Política y Gobierno
Episodios
  • John Crowley, CEO of BIO, Discusses The Biology Century and The Convergence of Public Health, Economic Growth, and National Security

    John Crowley, CEO of BIO, Discusses The Biology Century and The Convergence of Public Health, Economic Growth, and National Security
    Sep 30 2025
    John Crowley, President and CEO of BIO, shared his journey from business to biotech after his daughter Megan was diagnosed with Pompe Disease. He emphasized the importance of time in biotech, highlighting the transformation of cystic fibrosis treatment from a death sentence to a normal life expectancy. Crowley discussed the role of AI and machine learning in accelerating drug development, the need for a modernized FDA, and the importance of access to medicines. He advocated for a 21st Century Access Act to address barriers to medication. Crowley also mentioned his military service and his role in advocating for biotechnology to enhance public health, economic growth, and national security.John Crowley's Introduction and Personal BackgroundMaria Thacker Gothe introduces John Crowley, President and CEO of BIO, the Biotechnology Innovation Organization.John Crowley shares his background, including his early career in business and his transition into the world of science and medicine.John recounts the diagnosis of his daughter Megan with Pompe Disease, a rare form of muscular dystrophy, and the emotional journey that followed.He describes the initial shock and subsequent determination to learn about the disease and find a treatment.The Journey to Develop a Treatment for Pompe DiseaseJohn explains the process of learning about Pompe Disease, including the genetic aspects and the buildup of glycogen in Megan's muscles.He details the early research efforts and the realization that time was crucial in developing a treatment.John highlights the importance of collaboration with researchers and the development of a medicine that saved Megan and her brother Patrick's lives.He shares the progress his children have made, including Megan's education and career in social work and Patrick's work in a flower shop.John Crowley's Role at BIO and Advocacy for BiotechnologyMaria Thacker Gothe asks John about his priorities at BIO and how he sees biotechnology unleashing its potential.John emphasizes the importance of science policy, the need for more capital, and a business mindset in advancing biotechnology.He discusses the success stories in biotechnology, such as the transformation of cystic fibrosis treatment, and the need for more breakthroughs.John outlines the three main reasons for supporting biotechnology: public health, economic growth, and national security.The Role of AI and Machine Learning in BiotechnologyMaria and John discuss the potential of AI and machine learning in compressing the development pipeline in biotechnology.John shares examples of AI's current and future impact on medicine, including improving physician efficiency, aiding in diagnosis, and enhancing drug development.He highlights the potential of AI in understanding complex biological systems and improving clinical trial efficiency.John emphasizes the need for ethical principles and guardrails to ensure AI's responsible use in biotechnology.Challenges and Opportunities in BiotechnologyMaria and John discuss the challenges of accessing capital and the importance of reducing the time and cost of developing new medicines.John mentions the role of family offices, sovereign wealth funds, and new pools of capital in supporting biotechnology.He emphasizes the need for a modernized FDA and a more efficient clinical trial paradigm to speed up innovation.John highlights the importance of storytelling and advocacy in building support for biotechnology and ensuring access to life-saving medicines.Building a Successful Biotech Ecosystem in GeorgiaMaria asks John for advice on building a successful biotech ecosystem in Georgia.John emphasizes the importance of purposeful investment in workforce development, from high school STEM programs to vocational training and university education.He highlights the need for a pro-business environment and entrepreneurship culture to attract and retain biotech companies.John suggests looking at best practices from other successful biotech hubs and customizing them to Georgia's needs.The Importance of Access to MedicinesJohn discusses the moral obligation to ensure access to life-saving medicines and the role of the social contract between patients, insurers, and pharmaceutical companies.He criticizes the current system of step edits and prior authorizations, which can delay patient access to necessary treatments.John calls for a 21st Century Access Act to address barriers to access and ensure that all patients can receive the medicines they need.He emphasizes the need for transparency and reform in the pharmacy benefit manager (PBM) system to reduce costs and improve patient access.Personal Reflections and Future GoalsMaria asks John to share something most people don't know about him.John reveals that he is a grandfather to two beautiful grandchildren and has served in the United States Navy, including during the global war on terrorism.He expresses his commitment to continuing his work in biotechnology and advocating ...
    Más Menos
    40 m
Todavía no hay opiniones